ALSO NOTED: Mylan gets Florida's OK to sell thyroid med; Labopharm hits endpoint with Trazodone;

> A Florida judge has cleared the way for Mylan to sell its generic version of Abbott Laboratories' Levothyroxine Sodium thyroid med in the state. Report

> Labopharm's new once-daily Trazodone hit antidepressant study endpoints. Release

> APP Pharmaceuticals got the FDA nod for two copycat drugs: its version of Bedford Laboratories' apnea drug Cafcit and its form of Bristol-Myers Squibb's cancer treatment Blenoxane. Report

> Medtronic got the FDA's approval to sell a neurostimulation system for treating chronic pain. Report

> Alkermes plans to repurchase $60 million in common stock, using cash at least in part from its recent sale of a stake in Reliant Pharmaceuticals. Report

> PPD says it's inked a deal to buy InnoPharm, an independent contract research organization based in Russia. Report

> Icagen has triggered an option to sell $10 million worth of stock to Pfizer. Report

> The Star-Ledger offers a new perspective on the investment scene in biotechnology. Analysts say the credit crunch has put a squeeze on private equity groups who can no longer use cheap debt to buy into developers and then flip them. Report

> Carl Icahn is claiming that some biotechs must merge with Big Pharma--and that Biogen Idec is one of them. Report

And Finally... Memorial Sloan-Kettering Cancer Center no longer takes industry money to finance continuing medical education. Here's how. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.